Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

Wednesday, January 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

AbbVie is focused on pipeline expansion and diversification to address the upcoming patent cliff, with significant financial ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish strong. | UCB, AbbVie and Legend Biotech are among the companies ...

These stocks offer impressive long-term upside with downside protection.

Johnson & Johnson ( JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This ...

AbbVie Inc.’s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company’s current president and chief operating officer, Robert Michael.